Race Oncology (ASX:RAC) shares jump on positive Zantrene AML trial results

Be the First to Comment Read

Race Oncology (ASX:RAC) shares jump on positive Zantrene AML trial results

Leukemia is cancer of the bone marrow
Image source: © Angellodeco    | Megapixl.com


  • Race Oncology has received encouraging results from the first-stage trial of Zantrene in relapsed or refractory Acute Myeloid Leukaemia.
  • The very heavily pre-treated AML patient population has shown encouraging clinical responses.
  • The trial will now enter the Phase 2 stage.

Shares of Race Oncology Limited (ASX:RAC) jumped nearly 6% to AU$1.845 in the early hours of 27 May 2022 after a crucial company update.

The precision oncology company has received positive results from Phase 1b stage of the relapsed or refractory Acute Myeloid Leukaemia (R/R AML) trial. Leukaemia is the cancer of body's blood-forming tissues, including the bone marrow and the lymphatic system. Primary refractory or relapsed AML is a serious therapeutic challenge as it has a very poor prognosis.

Related read: Race Oncology (ASX:RAC) receives RGO nod for Zantrene human trial

Positive data from the first-stage trial

The Phase 1b dose escalation stage of the Phase 1b/2 Zantrene® study involving six patients took place at Chaim Sheba Medical Centre, Israel.

Primary endpoint of the trial - establishing the recommended dose to be used in the subsequent Phase 2 expansion (efficacy) stage.

The trial received very encouraging efficacy results in the refractory patient population.

Image source: © 2022 Kalkine Media®

Data: company update

Three (1 CR and 2 PR) out of five patients were bridged to an allogenic stem cell transplant. Bridging is a crucial positive outcome in AML treatment as it provides long-term remission to the patient.

Study Lead Prof Arnon Nagler said:The encouraging results of our Phase I study with Zantrene monotherapy and moreover the current Phase II study altogether with Zantrene in combination in extremely heavily treated advanced high risk AML patients are encouraging and may indicate a role for Zantrene in modern AML treatment paradigm to the benefit of our patients.”

Road ahead - Phase 2 efficacy stage

Now, the trial will advance to the Phase 2 efficacy (expansion) stage using a 4-day schedule of Zantrene®, combined with fludarabine and clofarabine. The open-label trial will recruit 17 patients and is expected to complete in 20-30 months.

Zantrene®, a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein, is a phase 2/3 cancer drug candidate of RAC. Race is exploring the use of Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

Also read: WFL, OSL, AVE: Three ASX healthcare stocks with over 20% QTD returns


Speak your Mind

Featured Articles

kalkine logo


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK